Hennessy Advisors Inc. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 24.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 85,199 shares of the biopharmaceutical company

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,986,591 shares of th

Van ECK Associates Corp trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 40.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 716,459 shares of the biopharmace

Flputnam Investment Management Co. redujo sus participaciones en Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) en un 48,8% en el segundo trimestre, según la compañía en su presentación más reciente ante la SEC. La firma poseía 70.944 acciones de la biofarmacéutica.

Gilead Sciences stock has a new HIV catalyst after the FDA cleared Bixlenvo on August 28, 2026. The

Royal London Asset Management Ltd. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 551,867 shares of the biopharmaceutical company

Nissay Asset Management Corp Japan lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 371,019 shares

Rakuten Investment Management Inc. increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 16.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 299,116 shares of the biopharmaceutical com

Braun Stacey Associates Inc. acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 102,562 shares of the biopharmaceutical company

Archer Investment Corp acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,578 shares of the biopharmaceutical com

Beacon Pointe Advisors LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 25.7% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 66,695 shares of the biopharmaceutical comp

BNP Paribas boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 20.7% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 118,671 shares of the biopharmaceutical compan

Wellington Management Group LLP reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,699,683 shares of the biopharmaceutical c

Gilead Sciences stock trades up after the FDA approved its new once-daily HIV regimen Bixlenvo, whil

Glenview Trust Co acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 192,157 shares of the biopharmaceuti

United Capital Financial Advisors LLC lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 25.3% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 108,152 shares of the biopharmaceuti

Public Employees Retirement System of Ohio lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 8.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 519,677 shares of the biopharmaceutical company